Guochuan Emil Tsai

USPTO Granted Patents = 34 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 11)

EPO Patents = 6 (Patent Applications = 17)

Average Co-Inventor Count = 2.7

ph-index = 5

Forward Citations = 55(Granted Patents)

Company Filing History:

28 out of 29

Syneurx International (taiwan) Corp.

patents

5 out of 89

Los Angeles Biomedical Research Institute at Harbor-ucla Medical Center

patents

1 out of 1

Synenrx International (taiwan) Corp.

patent

Years Active: 2017-2024

Loading Chart...

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12178804 - Salts of cycloserine compounds and applications thereof (2024-12-31),

2. 11793823 - Compounds and pharmaceutical uses thereof (2023-10-24),

3. 11779561 - Compounds and pharmaceutical uses thereof (2023-10-10),

4. 11753400 - D-amino acid oxidase inhibitors and therapeutic uses thereof (2023-09-12),

5. 11739046 - Co-crystals of lithium benzoate and uses thereof (2023-08-29),

6. 11731928 - Co-crystals of sodium benzoate and uses thereof (2023-08-22),

7. 11529342 - Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical (2022-12-20),

8. 11382924 - Compounds and pharmaceutical uses thereof (2022-07-12),

9. 11369579 - Polymorphic forms of sodium benzoate and uses thereof (2022-06-28),

10. 11291654 - Formulations of cycloserine compounds and applications thereof (2022-04-05),

11. 11278509 - Lithium salts of N-substituted glycine compounds and uses thereof (2022-03-22),

12. 11202791 - Compositions containing tannic acids and uses thereof (2021-12-21),

13. 11154531 - Compounds and pharmaceutical uses thereof (2021-10-26),

14. 11008277 - Co-crystals of sodium benzoate and uses thereof (2021-05-18),

15. 10927138 - Inhibitors of D-amino acid oxidase (DAAO) and uses thereof (2021-02-23),

Title: Innovations of Guochuan Emil Tsai: A Trailblazer in Pharmaceutical Patents

Introduction: Guochuan Emil Tsai, located in Pasadena, California, is an esteemed inventor with a remarkable portfolio of 34 patents. His contributions to the field of pharmaceutical compounds focus on advancements that enhance stability and therapeutic efficacy.

Latest Patents: Among his latest innovations, Tsai has developed salts of cycloserine compounds and their applications. This innovation introduces salts characterized by the formula [A][B], where [A] represents a cation form of a cycloserine compound and [B] is an anion from a specified compound. These salts exhibit significantly improved properties, such as increased stability and decreased hygroscopicity. Furthermore, Tsai has provided methods for treating and reducing the risk of neuropsychiatric disorders and bacterial infections, including tuberculosis, through the administration of these compositions. Additionally, he has patented a compound of Formula (I), featuring a range of therapeutic uses, emphasizing its potential in advanced pharmaceutical applications.

Career Highlights: Tsai has worked with prominent institutions such as Syneurx International Corp. and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. His expertise and innovative spirit have made substantial contributions to pharmaceutical research and development.

Collaborations: Throughout his career, Guochuan Emil Tsai has collaborated with notable colleagues such as Ching-Cheng Wang and Tien-Lan Hsieh. These collaborations have led to significant advancements in the therapeutic applications of his patented compounds.

Conclusion: Guochuan Emil Tsai stands out as a pioneering inventor in the pharmaceutical field, with a strong emphasis on enhancing compound stability and therapeutic potential. His continued work and dedication to innovation remain pivotal in advancing medical treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.